Show simple item record

dc.contributor.authorMoore, James V
dc.date.accessioned2011-03-13T00:10:23Z
dc.date.available2011-03-13T00:10:23Z
dc.date.issued1984-05
dc.identifier.citationDifferential effect of IP- and IV-injected nitrogen mustard on subsequently-irradiated intestinal crypts: implications for 'dose-effect factors' predicted by experimental, combined modality therapy. 1984, 57 (677):403-7 Br J Radiolen
dc.identifier.issn0007-1285
dc.identifier.pmid6722435
dc.identifier.doi10.1259/0007-1285-57-677-403
dc.identifier.urihttp://hdl.handle.net/10541/124432
dc.description.abstractIn experimental chemotherapy-radiotherapy, cytotoxic drugs are almost invariably injected by the intraperitoneal (IP) route. This contrasts with normal clinical practice, which is to employ the intravenous (IV) route. We have used a clonogenic assay of gastrointestinal (GI) injury in mice to show that a given administered dose of nitrogen mustard (HN2), injected IP, results in a much greater reduction in the subsequent radiation dose required to achieve an isoeffect, than if the drug is injected IV. At an administered dose of 3.5 mg kg-1 of HN2 (the animal LD10/30 for IP injection), the radiation dose-reduction factor for 10% survival of intestinal crypts, was 1.94 for IP HN2 and only 1.28 for IV HN2. Even the grossly-equitoxic (mouse LD10/30) dose of IV HN2 resulted in a smaller predicted radiation dose reduction for GI injury, by a factor of 1.45. The validity of using the IP route in combined chemotherapy-radiotherapy studies designed to generate quantitative estimates of toxicity is discussed.
dc.language.isoenen
dc.subject.meshAnimals
dc.subject.meshCell Survival
dc.subject.meshClone Cells
dc.subject.meshCombined Modality Therapy
dc.subject.meshDose-Response Relationship, Drug
dc.subject.meshDose-Response Relationship, Radiation
dc.subject.meshGamma Rays
dc.subject.meshInjections, Intraperitoneal
dc.subject.meshInjections, Intravenous
dc.subject.meshJejunum
dc.subject.meshMale
dc.subject.meshMechlorethamine
dc.subject.meshMice
dc.subject.meshMice, Inbred Strains
dc.titleDifferential effect of IP- and IV-injected nitrogen mustard on subsequently-irradiated intestinal crypts: implications for 'dose-effect factors' predicted by experimental, combined modality therapy.en
dc.typeArticleen
dc.identifier.eissn1748-880X
dc.contributor.departmentPaterson Laboratories, Christie Hospital and Holt Radium Institute, Wilmslow Road, Withington, Manchester M20 9BX, UKen
dc.identifier.journalThe British journal of Radiologyen
html.description.abstractIn experimental chemotherapy-radiotherapy, cytotoxic drugs are almost invariably injected by the intraperitoneal (IP) route. This contrasts with normal clinical practice, which is to employ the intravenous (IV) route. We have used a clonogenic assay of gastrointestinal (GI) injury in mice to show that a given administered dose of nitrogen mustard (HN2), injected IP, results in a much greater reduction in the subsequent radiation dose required to achieve an isoeffect, than if the drug is injected IV. At an administered dose of 3.5 mg kg-1 of HN2 (the animal LD10/30 for IP injection), the radiation dose-reduction factor for 10% survival of intestinal crypts, was 1.94 for IP HN2 and only 1.28 for IV HN2. Even the grossly-equitoxic (mouse LD10/30) dose of IV HN2 resulted in a smaller predicted radiation dose reduction for GI injury, by a factor of 1.45. The validity of using the IP route in combined chemotherapy-radiotherapy studies designed to generate quantitative estimates of toxicity is discussed.


This item appears in the following Collection(s)

Show simple item record